Posted on

What is autism? It’s changing.

Podcast: Play in new window | Download

Subscribe: RSS

This week, the Autism and Developmental Disabilities Network, or ADDM, was used to look at the changes across time in co-occuring conditions in people with autism, like ADHD, depression, anxiety, language delay and other developmental delay.  They found the frequency of 8 year olds with autism with these co occurring conditions is increasing.  So is the percent of people with autism with intellectual disability.  The data continues to show that in many people, what was autism 20 years ago, is not the same autism seen today.  While depression and anxiety have already been established as co occurring issues, things like hoarding are just starting to be examined.   These results suggest that co-occurring conditions may be one of the features of autism that can separate people into different groups, to improve intervention and treatment opportunities.

https://www.ncbi.nlm.nih.gov/pubmed/30227350

https://www.ncbi.nlm.nih.gov/pubmed/30178724

Posted on

Just listen to Nancy Reagan: say NO to MDMA

Podcast: Play in new window | Download

Subscribe: RSS

This week’s podcast begins with a comment on the debate over ABA, helpful or harmful?  But the big news this week is an analysis of very early, but very published data, on the use of MDMA, or “ecstasy” or “Molly” in people with autism.  Called an “empathogen”, MDMA can elicit feelings of warmth, love and need to cuddle.  However, it has a dark side. MDMA is a neurotoxin.  It kills serotonergic brain cells.  There is no known safe dose.  Researchers studied and found weak evidence that it reduces social anxiety in people with autism.  Social anxiety isn’t a core symptom of autism and thank you to Larry Scahill at Emory University to provided an expert description of each.  While we will not comment on every negative study out there, this one is worth noting.  When someone offers you MDMA, JUST SAY NO.

https://www.ncbi.nlm.nih.gov/pubmed/30196397

 

Posted on

Can IGF-1 treat autism symptoms? A clinical trial aims to find out

Podcast: Play in new window | Download

Subscribe: RSS

A full transcript of this podcast episode can be read on the ASF blog here.

Researchers at Mount Sinai led by Alex Kolevzon are running a clinical trial of the compound insulin-like growth factor 1 (IGF-1) for children with idiopathic autism. Dr. Kolevzon’s team previously demonstrated the safety and feasibility of IGF-1 in treating Phelan-McDermid syndrome, a single-gene form of autism. Particularly, the IGF-1 treatment improved symptoms of social impairment and repetitive behaviors, which are core symptoms of autism. Expanding their investigation into idiopathic autism, the researchers are working hard to make sure families can comfortably and knowledgeably participate in the clinical trial. Mahir Rahman spoke with Dr. Kolevzon about the study and where it hopes to go. Interested in joining the study? Go here to learn more.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326443/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450831/

Posted on

Children are not small adults

Podcast: Play in new window | Download

Subscribe: RSS

Cathy Lord and her colleagues have been studying a group of people with autism from age 2, all the way through adulthood, at age 19.  Her colleague and first author Vanessa Hus-Bal who is leading the efforts to study adults at a new institute at Rutgers University, talks about the findings and what they mean for people with autism as they get older, and points out the implications on intervention.  Also, the stress response is different in autistic people, but is it different in adolescents and adults, and does it change as people get older?  A social stressor is used to identify how they are different and what it means for treatment.